Key facts
- This page summarizes Carl C. Dockery's Form 5 filing for AYTU BIOPHARMA, INC (AYTU).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Oct 2025, 15:56.
Key filing fact
Ownership activity is grounded in SEC Form 5 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Sale
No transaction description listed
Additional SEC filing notes
Footnote F1
The Reporting Person's purchase and sale of AYTU common shares (the "Shares") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 209 Shares sold on December 30, 2020, with the Reporting Person's purchase of 10,000 Shares on November 18, 2020. After taking into consideration the Issuer's 10:1 reverse stock split on December 10, 2020, the price for the November 18, 2020, purchase was $9.23 per share, or a total purchase price of $1,929.07 for 209 Shares. The total sale price of 209 Shares on December 30, 2020, was $1,256.09. THE REPORTING PERSON DID NOT REALIZE ANY PROFIT IN CONNECTION WITH THE SHORT-SWING PURCHASE AND SALE.
Footnote F2
Represents total Shares held following stock splits on June 30, 2016 (12:1), August 25, 2017 (20:1), August 13, 2018 (20:1), December 10, 2020 (10:1) and January 6, 2023 (20:1).
Footnote F3
Includes 10,000 restricted shares granted to the Reporting Person on October 3, 2025, and reported on a Form 4 filed with the Securities and Exchange Commission on October 7, 2025.
SEC remarks
The total direct shares reported above in Table I, Column 5, include a correction to an error in the total number of securities reported in Column 5 of Table I on the Form 4 filed with the Securities and Exchange Commission on April 16, 2021.